German biotechnology company BioNTech SE and Chinese pharmaceutical company Shanghai Fosun Pharmaceutical (Fosun) will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China, Reuters news agency reported on Wednesday.
In a statement, BioNTech and Fosun said that this vaccine, known as BNT162b2, will be tested on volunteers at the Jiangsu Provincial Centre for Disease Control and Prevention to assess safety and immunogenicity, eyeing future approval in China.
In addition, BioNTech is working with US pharmaceutical company Pfizer Inc on the vaccine.
The companies had said last week they were hoping to win approval in the US and Europe this year, after trial results showed the compound had a 95% efficacy rate and caused no serious side effects.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA